DexCom Inc. (DXCM)

378.31
NASDAQ : Health Technology
Prev Close 361.83
Day Low/High 364.00 / 379.09
52 Wk Low/High 115.90 / 428.59
Avg Volume 1.88M
Exchange NASDAQ
Shares Outstanding 92.30M
Market Cap 33.40B
EPS 1.10
P/E Ratio 224.74
Div & Yield N.A. (N.A)

Latest News

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Why Worry About Negative Arguments When the Price Action Says They Don't Matter?

Why Worry About Negative Arguments When the Price Action Says They Don't Matter?

The reason that the coronavirus hasn't mattered to the market is because the market keeps going up.

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.

Healthy Upside Potential In Medical Devices and Services Stocks

Healthy Upside Potential In Medical Devices and Services Stocks

Some of the best opportunities are in lesser-known niche markets such as medical devices and services.

Can DexCom Trade Still Higher or Did We Witness a Blow Off?

Can DexCom Trade Still Higher or Did We Witness a Blow Off?

Let's check the charts and indicators before answering the $64,000 question.

Dexcom Looks Poised to Build on Its Big Gap Up

Dexcom Looks Poised to Build on Its Big Gap Up

The maker of glucose monitoring equipment saw its shares shoot higher last week on a big earnings beat and the rise may not be over.

China Gets Serious, Trading Roku: Market Recon

China Gets Serious, Trading Roku: Market Recon

As for pressure on the Chinese side, I think a September 17.8% decline in exports to the U.S. compounded on top of a 22% decline in August speaks for itself.

U.S. Treasury Yield Curve, Oil Market Valuations, Trading Adobe: Market Recon

U.S. Treasury Yield Curve, Oil Market Valuations, Trading Adobe: Market Recon

OPEC forecasts declining demand for OPEC oil, not a decline in global demand. That distinction is key.

Dexcom Looks Like It Can Finally Break Out on the Topside

Dexcom Looks Like It Can Finally Break Out on the Topside

Let's check the charts and indicators on the glucose-monitoring company.

Jim Cramer: Blockbuster Ideas That I Know Would Move Apple's Needle

Jim Cramer: Blockbuster Ideas That I Know Would Move Apple's Needle

What would the people who help determine AAPL's stock price really want?

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

A Technical Strategy for Tandem Diabetes Care

A Technical Strategy for Tandem Diabetes Care

Are we late to the game with the stock up so much?

The Three Bullish Charts of DexCom

The Three Bullish Charts of DexCom

With more gains likely on the charts let's come up with a strategy to take advantage of this opportunity.

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

After a slump early last year, the smartwatch's sales have been rebounding. New features unveiled at Apple's WWDC conference could aid its momentum later this year.

Jim Cramer: Report of Apple's Diabetes Test Isn't a Reason to Own the Stock

Jim Cramer: Report of Apple's Diabetes Test Isn't a Reason to Own the Stock

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said reports of Apple developing a diabetes testing product is not a reason to own the stock.

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Old-line momentum favorites fare well.

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

These companies show signs of a change of direction.

DexCom: Look, but Don't Touch

DexCom: Look, but Don't Touch

The medical device company has been trading sideways for a long time and is likely to continue in the manner.

Dexcom downgraded at Morgan Stanley

Dexcom upgraded at Oppenheimer

Dexcom upgraded at BTIG

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

But several airline and retail stocks are proving highly volatile.

Sohn Picks Revisited: Mixed Results From David Einhorn & Jeffrey Smith

Sohn Picks Revisited: Mixed Results From David Einhorn & Jeffrey Smith

Results on conference picks are split as hedge fund industry contends with criticism.

2016 Sohn Investment Conference Live Blog: Session 2

2016 Sohn Investment Conference Live Blog: Session 2

David Einhorn, Jim Chanos presentations close out 2106's Sohn Investment Conference.

Mobile App Spurring Global Sales Says DexCom CEO

Mobile App Spurring Global Sales Says DexCom CEO

Shares of DexCom have bounced back 15% since hitting a 52-week low early last month, yet are still down 20% so far in 2016.